

CALLISTO PHARMACEUTICALS INC  
Form 8-K  
February 24, 2006

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

FORM 8-K

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 17, 2006

**Callisto Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation or organization)

001-32325  
(Commission File Number)

13-3894575  
(IRS Employer Identification No.)

420 Lexington Avenue, Suite 1609  
New York, New York 10170  
(Address of principal executive offices)

Registrant's telephone number, including area code: (212) 297-0010

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**Item 1.01**

**Entry into a Material Definitive Agreement.**

On February 17, 2006, Pamela Harris, the Chief Medical Officer of Callisto Pharmaceuticals, Inc., a Delaware corporation (the “Company”) resigned from the Company. As a result the employment agreement between Dr. Harris and the Company dated as of March 28, 2005, as amended, was terminated.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 23, 2006

CALLISTO PHARMACEUTICALS

By: /s/ Gary S. Jacob  
Gary S. Jacob, Ph.D.  
Chief Executive Officer

---